Welcome to our dedicated page for Bioceres Crop Solutions SEC filings (Ticker: BIOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking drought-tolerant HB4 approvals, biological fertilizer margins, and multi-segment revenue splits across continents can make Bioceres Crop Solutions Corp filings feel like a maze. If you have ever searched the 200-page annual report for R&D milestones—or tried lining up soybean trait progress with executive stock sales—you already know the challenge.
Stock Titan solves this complexity. Our AI reads every submission on EDGAR, tags the passages investors ask for, and delivers Bioceres Crop Solutions insider trading Form 4 transactions and Bioceres Crop Solutions quarterly earnings report 10-Q filing in plain language. Need rapid context? Get Bioceres Crop Solutions SEC filings explained simply through instant summaries that spotlight HB4 regulatory updates, segment EBITDA drivers, and climate-tech subsidies. Real-time alerts surface each Bioceres Crop Solutions Form 4 insider transactions real-time, while keyword navigation jumps you to biologics revenue or drought-tolerance cost curves inside the 10-K.
Whether you are comparing fertilizer volumes quarter-over-quarter or reviewing the Bioceres Crop Solutions proxy statement executive compensation, every document is linked, searchable, and annotated. Explore our AI-guided Bioceres Crop Solutions annual report 10-K simplified, dive into Bioceres Crop Solutions earnings report filing analysis, or monitor Bioceres Crop Solutions 8-K material events explained after new seed-trait approvals. From monitoring Bioceres Crop Solutions executive stock transactions Form 4 before planting season to understanding understanding Bioceres Crop Solutions SEC documents with AI, Stock Titan equips you with the insights needed to act, not just read.
BAF Latam Credit Fund B.V. reports beneficial ownership of 3,461,430 ordinary shares of Bioceres Crop Solutions Corp. (BIOX), representing 5.52% of the class based on the issuer's reported outstanding share count of 62,712,602. The filing states BAF holds sole voting power and sole dispositive power over the disclosed shares.
The statement was submitted on Schedule 13G and includes an Item 10 certification that the securities were not acquired to change or influence control of the issuer, indicating the filer describes the position as passive under the Schedule 13G framework.
Jasper Lake Ventures One LLC and Noah Kolatch report a combined economic interest of 7,382,919 ordinary shares in Bioceres Crop Solutions Corp. (BIOX), representing approximately 10.6% of the outstanding class on the calculation in this filing. That position includes 397,000 Ordinary Shares held directly by Jasper Lake plus the Ordinary Shares issuable upon conversion of a secured guaranteed convertible Note into 6,985,919 Ordinary Shares as of this filing.
The Notes were purchased under a Note Purchase Agreement as part of a $55,000,000 issuance, with Jasper Lake acquiring $33,500,000 in principal. The Notes bore regular interest at 9.00% per year until June 15, 2025 and 15.00% thereafter, mature on August 31, 2027, and are convertible into Ordinary Shares using a Strike Price originally equal to $6.00 subject to customary anti-dilution adjustments and price-based reductions in certain financings. PIK interest accrues and compounds, increasing the Accreted Principal Amount and the number of shares issuable on conversion.
Under an amendment, Noah Kolatch was appointed to the Issuer's Board and the Issuer also appointed Scott Croco and Milen Marinov; replacement-nomination rights for certain directors are described. The Reporting Persons state the acquisition was for investment purposes, note registration rights were granted, and disclose they may engage with management or consider actions including acquiring or disposing of securities, hedging, or proposing strategic alternatives.
Bioceres Group Limited and affiliates trimmed their stake in Bioceres Crop Solutions Corp. (BIOX) in Schedule 13D/A Amendment No. 15 dated 08 Aug 2025. The group’s beneficial ownership fell to 15,497,402 ordinary shares, equal to 24.7 % of BIOX’s 62,848,483 shares outstanding, down from 18,561,323 shares previously reported. The reduction—≈ 6.14 million shares—resulted from open-market sales and enforcement of pledge agreements executed under the New York UCC to satisfy financial obligations.
Breakdown of holdings: Bioceres Group Limited holds 70,785 shares directly and, through subsidiaries, shares voting/dispositive power over 15.4 million. Subsidiaries Bioceres LLC and THEO I SCSp own 14,989,117 (23.8 %) and 437,500 (0.7 %) shares, respectively. Of the total, 3,076,079 shares are subject to a 2019 Shareholders Agreement giving the group shared voting rights.
Key takeaways for investors: (1) Bioceres entities remain BIOX’s largest shareholder but have reduced influence by ~4.8 percentage points; (2) Sale was motivated by obligation settlement, not stated strategic change; (3) No new plans or proposals affecting BIOX were disclosed.
The excerpt provided for Bioceres Crop Solutions Corp.’s 6-K filing consists almost entirely of internal XBRL element names (e.g., biox:PublicCorporateBondsMember, ifrs-full:ParentMember) and date delimiters. It contains no narrative disclosure, financial metrics, transaction descriptions, or explanatory notes. Because the submission lacks quantitative data or management commentary, there is insufficient publicly disclosed information to determine the nature, magnitude, or timing of any “major transactions” referenced in the metadata.
Without contextual narrative or figures, investors and analysts cannot assess material impacts on revenue, earnings, cash flow, leverage, or strategic positioning. As such, no meaningful financial analysis can be produced from the content supplied.
FAQ
What is the current stock price of Bioceres Crop Solutions (BIOX)?
What is the market cap of Bioceres Crop Solutions (BIOX)?
